Brief Reports Open Access
Copyright ©The Author(s) 2003. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 15, 2003; 9(10): 2366-2369
Published online Oct 15, 2003. doi: 10.3748/wjg.v9.i10.2366
Molecule action mechanisms of NM-3 on human gastric cancer SGC-7901 cells in vivo or in vitro
Jin-Shui Zhu, Bo Shen, Jin-Lian Chen, Guo-Qiang Chen, Xiao-Hu Yu, Hua-Fang Yu, Zu-Ming Zhu, Affiliated Sixth People’s Hospital, Shanghai Jiaotong University, Shanghai 200233, China
Guo-Qiang Chen, Shanghai Experimental Animal Center, Chinese Academy of Sciences, Shanghai 200233, China
Author contributions: All authors contributed equally to the work.
Supported by Shanghai Natural Science Foundation, No.02ZB14072
Correspondence to: Jin-Shui Zhu, Department of Gastroenterology, Affiliated Sixth People’s Hospital, Shanghai Jiaotong University, Shanghai 200233, China. zhujs1803@hotmail.com
Telephone: +86-21-64369181 Exit 8351 Fax: +86-21-54778507
Received: May 12, 2003
Revised: May 25, 2003
Accepted: June 2, 2003
Published online: October 15, 2003

Abstract

AIM: To study the molecule action mechanisms of NM-3 on the growth of human gastric cancer SGC-7901 cells in vivo or in vitro.

METHODS: SGC-7901 from human non-differentiated gastric cancer cell line was cultured with NM-3 at 100 mg/mL for 24 h. We observed its inhibitory rate and the density of micro-vascular growth in grafted mice with human gastric cancer SGC-7901. The apoptosis of human gastric cancer SGC-7901 was revealed in NM-3 treatment group by using terminal deoxynucleotidyl transferase-mediated deoxy-uridine triphosphate-fluorescene nick end labeling (TUNEL) method and flow cytometry analysis.

RESULTS: The growth of SGC-7901 cells was markedly inhibited compared with control growp, which was smaller than that in normal saline control group (4.17 g ± 0.22 g vs 9.45 g ± 1.38 g, P < 0.01). The level of apoptosis of human gastric cell line SGC-7901 was obviously increased in NM-3 treatment group at 1 mg.L-1 for 24 h. NM-3 inducing apoptotic index in NM-3 plus carboplatin group was 3.5 times that of carboplatin control group (TUNEL: 27.98% ± 6.12% vs 12.94% ± 2.12%, FACScan: 26.86% ± 5.69% vs 11.86% ± 1.09%, P < 0.01). Western blot analysis showed that the apoptotic index of human gastric cancer was elevated for 12, 24 and 36 h with an evident time-effect relationship in groups at 100 mg.L-1. NM-3 enhanced the inhibitive effects and sensitivity of chemotherapy for human gastric cancer in nude mice. These results suggested that NM-3 played a key inhibitive role in the growth of grafted human gastric cancer in nude mice.

CONCLUSION: NM-3 can inhibit the growth of human gastric cancer cell line SGC-7901, and enhance the sensitivity of carboplatin on SGC-7901 and induced its apoptosis.




INTRODUCTION

Apoptosis plays a key role in the proliferation and turnover of malignant tumor cells. It has been known that its extent is often enhanced in gastric cancer by some anti-cancer drugs, such as chemotherapeutic drugs, hormones or immune agents, micro-vascular growth inhibitors have been proved to have some inhibitory effects on maligant tumors,especially on gastric tumors. But it has not been clear whether NM-3 is a micro-vascular inhibitive agent for solid tumor growth[1-3], it might suppress gastric cancer cell proliferation and cause tumor cell loss and nuclear condensation in vitro. Up to date, NM-3 is considered as the newest micro-vasular inhabitor[1-4]. Combined with carboplatin, it can soften hard lumps and dissolve phlegm, enhance apoptosis of human gastric cancer xenografts in nude mice. On the other hand, NM-3 can enhance the sensitivity of chemotherapeutic drugs on human gastric cancer. Based on previous studies, NM-3 exerts its effects on solid tumor growth by promoting apoptosis of human gastric cancer cell SGC-7901 and increasing the suppressive effects of carboplatin.

MATERIALS AND METHODS
Materials

A human gastric cancer cell line SGC-7901 grafted onto nude mice was used as the animal model, the age of these 60 mice was 6-7 weeks old female balb/c-nu/nu mice (weight 18-22 g) and a human gastric cancer cell line SGC-7901 was obtained from Shanghai Tumor Institute (No: 01842). The animals were subcutaneously xerografted under abdominal skin with the SGC-7901 cell line. The tumor transplantation procedure was described previously. The animal model and SGC-7901 cell line were obtained from Shanghai Experimental Animal Centre, Chinese Academy of Sciences.

NM-3 was composed of 2-c8-hydroxy-6-methoxy-1-oxo-1 h-2-benzopyran-3-yd, concentrantion of NM-3 was 100 mg·L-1, the concentration of carboplatin was 100 mg·L-1.

Methods

Experimental schedule: After grafting, these nude mice were randomly divided into 3 groups: control group and two experimental groups assigned to receive NM-3 or carboplatin respectly. Each experimental mouse in two experimental groups was given a 0.5 mL dose of NM-3 drug via intra-abdominal injection or gastric perfusion (empty control group) once every three days over a 40-day period beginning at 1st day after being xerografted. The control animals received normal saline according to the same schedule by gastric perfusion. The animals were killed 41 d after being xerografted.

In our study, NM-3 induced gastric cancer cell apoptosis, and enhanced the chemotherapeutic sensitivity of human gastric cancer cell line SGC-7901 on carboplatin in vitro. Apoptosis induced by NM-3 needed further investigation.

Therapeutic effects on human gastric cancer cell growth were assessed. Tumor size was measured twice a week by multiplying two perpendicular diameter and tumor weight was determined immediately by electron balance after the animals were killed. Apoptotic cells and apoptotic index were determined by the terminal deoxynucleotidyl transferase-mediated deoxy-uridine triphosphate-fluorescene nick end labeling (TUNEL) method and flow cytometry analysis. Morphological atterations were observed with electron microscope.

Flow cytometry analysis: Propidium iodide (PI) staining was used for flow cytometric detection of apoptosis. 1 × 106 cells from each of the samples were treated with RNase and stained with PI. The apoptotic cells labled by DNA strand were measured with a flow cytometer (FACS Calibur,Becton Dickinson,U.S.A).The data from 1 × 106 cells/sample were collected,stored,and analyzed using CELLQUES’T and MODFITLT for macV1.01 software[4-12].

Statistical analysis

The results were expressed as x-±s, Student’s t test was used. P value < 0.05 was concidered significantly.

RESULTS
NM-3 inhibited growth of micro-vascular of tumor in nude mice with human gastric cancer SGC-7901

NM-3 group decreased signicantly the neo-microvascular density (1.17 ± 0.05 mm3) of gastric cancer tumor implanted onto nude mice was significantly decreased in NM-3 group compared with that in saline group (5.37 ± 1.12 mm3) and carboplatin group (4.72 ± 1.18 mm3, P > 0.05). The micro-vascular density in NM-3 combinated with carboplatin group (1.18 ± 0.05 mm3) was not significantly different from that in NM-3 group (P > 0.05, Table 1).

Table 1 Growth of neo-microvascular around gastric tumor supressed by NM-3 (x-±s).
TreatmentnDensity (mm3)
Carboplatin104.72 ± 1.18a
NM-3 plus carboplatin101.18 ± 0.05b
Saline105.37 ± 1.72
NM-3 enhanced sensitivity of carboplatin on human gastric cancer induced by apoptosis of human gastric cancer cell in vitro or in vivo

The apoptotic indix (AI) of SGC-7901 induced by carboplatin was enhanced in NM-3 group. The apoptotic indix (TUNEL: 27.98% ± 6.12%, FACScan: 26.86% ± 5.69%) was markedly increasd in that of carboplatin group by using either TUNEL method or flow cytometry analysis compared with the carboplatin group (TUNEL: 12.94% ± 2.12%, P < 0.01; FACScan: 11.86% ± 1.09%, P < 0.01). The apoptotic indix in NM-3 group (TUNEL: 16.47% ± 4.13% FACScan: 15.97% ± 1.49%) was higher than that in normal saline group (TUNEL 1.83% ± 0.12%, P < 0.01; FACScan: 1.06% ± 0.09%, P < 0.01, Table 2).

Table 2 Apoptotic indix (AI) of human gastric cancer line SGC-7901 enhanced by NM-3 in vitro (x-±s).
TreatmentnAI (TUNEL)%AI (FACScan)%
NM-31016.47 ± 4.13b15.97 ± 2.49b
Carboplatin1012.94 ± 2.12b11.86 ± 1.09b
NM-3 plus carboplatin1027.98 ± 6.12b26.86 ± 5.69b
Saline101.83 ± 0.121.06 ± 0.09
NM-3 effected on growth of xerografted human gastric cancer cell line SGC-7901 in nude mice

The tumor weight of nude mice in NM-3 group (4.17 ± 0.22 g) was obviously lower than that in normal saline controls (9.45 ± 0.38 g), the tumor size of the prior group (0.68 g ± 0.07cm3, P < 0.05) was smaller than that in normal saline control group (8.94 ± 1.46 cm3). The tumor weight and size of nude mice in NM-3 combinated with carboplatin group were 2.78 ± 0.18 g and 0.34 ± 0.02 cm3 respectively. However, those in NM-3 group were not significantly different compared with carboplatin group (4.46 ± 0.23 g, 0.71 ± 0.08 cm3) 7 weeks later. Tumor growth was (size and weight) markedly inhibited by treatment with NM-3 (P < 0.01). The tumor inhibitory rate of single NM-3 on tumors was 67.7%, that in NM-3 combinated with carboplatin group was up to 98.7% (Table 3).

Table 3 Growth of xerografted human gastric tumor affected by NM-3 in nude mice (x-±s).
TreatmentnWeight (g)Size (cm3)
NM-3104.17 ± 0.22a0.68 ± 0.07a
Carboplatin104.46 ± 0.23a0.71 ± 0.08a
NM-3 plus carboplatin102.78 ± 0.18b0.34 ± 0.02b
Saline109.45 ± 1.388.94 ± 1.46
DISCUSSION

Gastric cancer remains one of the most common causes of cancer-related death in the world. At present, gastric cancer is still diagnosed at its advanced stage in most patients throughout the world. Even with curative resection, they remain at a high risk of relapse[13-32]. Thus, there is a great need for effective adjuvant therapy for patients with gastric cancer. Our previous clinic paired comparative studies suggested that NM-3 had therapeutic effects on advanced gastric cancer. It could increase the surviving period of the patients, improve the life quality and increase the metastasis and recurrence after operation because of its lower toxic side-effect compared with intravenous chemical therapy[33-47]. Up to date, the effect of NM-3 on human gastric cancer has not been reported in the world. So we thought it is worth to make a further research on its anti-cancer mechanisms.

Gastric cancer is not only a disease with abnormal cell proliferation and differentiation, but also a disease with abnormal apoptosis. Enhanced apoptosis in human gastric cancer cells could be observed after treatmemt with 5-fluorouracil, cisplatin, arsenous oxide, etc. These data suggest that it is a therapeutic method for patients with gastric cancer to induce apoptosis of cancer cells[64]. The present study indicated that tumor growth was significantly inhibited by treatment with carboplatin or NM-3. The results obtained by TUNEL method and cytometry analysis suggested that gastric cancer cells were suppressed in vivo, NM-3 was related to the induction of apoptosis of human gastric cancer cell line SGC-7901. These data suggest that NM-3 can inhibit gastric cell proliferation. So inhibition of gastric cancer induced by NM-3 is also related to the suppression of its proliferation.

Apoptosis is a complex and active cellular process, whereby individual cells are triggered to undergo self-destruction in a manner that would neither injures neghiboring cells nor elicites any inflammatory reation. Various triggering factors initiate corresponding proteo-lysis cascade reaction depending on mitochondrion or APO 1\FAS\CD95 receptors mediate apoptotic pathways. There are oncogenes and tumor suppressor gene products in the regulation and execution of apoptosis. It has been proved[14-22] that p53, Rb, myc, ras, raf, play important roles in apoptosis and are thus named the guardians of genomes[23-44]. They monitor the state of DNA and cell cycle is blocked in case of DNA damage. This takes place through the induction of CIP/Swaf/p21. In the absence of phosphorylated active cyclin-dependent kinases, the cell cycle remains inactive (unphosphorylated).

This leads to activation of DNA repair machinery. If DNA repair fails, p53 will take over again and trigger apoptosis in a process that involves upregulation of the apoptosis-inducing bax and down-regulation of the apoptotic bal-2[45-60]. We also detected apoptosis-inhibiting member of the bcl-2 family[61-64]: bcl-2 mRNA. The interaction between NM-3 and gastric cancer cell SGC-7901 induced its apoptosis of gastric cancer cells, but further in vivo or in vitro studies are needed.

Footnotes

Edited by Wang XL

References
1.  Richardson M, Gunawan J, Hatton MW, Seidlitz E, Hirte HW, Singh G. Malignant ascites fluid (MAF), including ovarian-cancer-associated MAF, contains angiostatin and other factor(s) which inhibit angiogenesis. Gynecol Oncol. 2002;86:279-287.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 21]  [Cited by in F6Publishing: 25]  [Article Influence: 1.1]  [Reference Citation Analysis (0)]
2.  Basaki Y, Chikahisa L, Aoyagi K, Miyadera K, Yonekura K, Hashimoto A, Okabe S, Wierzba K, Yamada Y. gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. Angiogenesis. 2001;4:163-173.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 61]  [Cited by in F6Publishing: 63]  [Article Influence: 2.9]  [Reference Citation Analysis (0)]
3.  Yamamoto S, Yasui W, Kitadai Y, Yokozaki H, Haruma K, Kajiyama G, Tahara E. Expression of vascular endothelial growth factor in human gastric carcinomas. Pathol Int. 1998;48:499-506.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 47]  [Cited by in F6Publishing: 48]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]
4.  Li C, Guo B, Bernabeu C, Kumar S. Angiogenesis in breast cancer: the role of transforming growth factor beta and CD105. Microsc Res Tech. 2001;52:437-449.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 1]  [Reference Citation Analysis (0)]
5.  Zhai Y, Yu J, Iruela-Arispe L, Huang WQ, Wang Z, Hayes AJ, Lu J, Jiang G, Rojas L, Lippman ME. Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer. 1999;82:131-136.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 3]  [Reference Citation Analysis (0)]
6.  Masood R, McGarvey ME, Zheng T, Cai J, Arora N, Smith DL, Sloane N, Gill PS. Antineoplastic urinary protein inhibits Kaposi's sarcoma and angiogenesis in vitro and in vivo. Blood. 1999;93:1038-1044.  [PubMed]  [DOI]  [Cited in This Article: ]
7.  Zhai Y, Ni J, Jiang GW, Lu J, Xing L, Lincoln C, Carter KC, Janat F, Kozak D, Xu S. VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J. 1999;13:181-189.  [PubMed]  [DOI]  [Cited in This Article: ]
8.  Tsunemi T, Nagoya S, Kaya M, Kawaguchi S, Wada T, Yamashita T, Ishii S. Postoperative progression of pulmonary metastasis in osteosarcoma. Clin Orthop Relat Res. 2003;407:159-166.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 36]  [Cited by in F6Publishing: 45]  [Article Influence: 2.1]  [Reference Citation Analysis (0)]
9.  Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, Tutsch K, Dresen A, Geiger P, Pluda J. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2003;21:223-231.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 181]  [Cited by in F6Publishing: 172]  [Article Influence: 8.2]  [Reference Citation Analysis (0)]
10.  Anderson KC. Moving disease biology from the laboratory to the clinic. Semin Oncol. 2002;29:17-20.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 15]  [Cited by in F6Publishing: 16]  [Article Influence: 0.7]  [Reference Citation Analysis (0)]
11.  Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29:15-18.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1845]  [Cited by in F6Publishing: 1908]  [Article Influence: 86.7]  [Reference Citation Analysis (0)]
12.  Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol. 2002;29:10-14.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 448]  [Cited by in F6Publishing: 449]  [Article Influence: 20.4]  [Reference Citation Analysis (0)]
13.  Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol. 2002;29:3-9.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 209]  [Cited by in F6Publishing: 219]  [Article Influence: 10.0]  [Reference Citation Analysis (0)]
14.  Gee MS, Procopio WN, Makonnen S, Feldman MD, Yeilding NM, Lee WM. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol. 2003;162:183-193.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 165]  [Cited by in F6Publishing: 174]  [Article Influence: 8.3]  [Reference Citation Analysis (0)]
15.  Koyanagi S, Tanigawa N, Nakagawa H, Soeda S, Shimeno H. Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities. Biochem Pharmacol. 2003;65:173-179.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 365]  [Cited by in F6Publishing: 312]  [Article Influence: 14.9]  [Reference Citation Analysis (0)]
16.  Büchler P, Reber HA, Büchler M, Shrinkante S, Büchler MW, Friess H, Semenza GL, Hines OJ. Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas. 2003;26:56-64.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 152]  [Cited by in F6Publishing: 158]  [Article Influence: 7.5]  [Reference Citation Analysis (0)]
17.  Chlenski A, Liu S, Crawford SE, Volpert OV, DeVries GH, Evangelista A, Yang Q, Salwen HR, Farrer R, Bray J. SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res. 2002;62:7357-7363.  [PubMed]  [DOI]  [Cited in This Article: ]
18.  Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res. 2002;62:7247-7253.  [PubMed]  [DOI]  [Cited in This Article: ]
19.  Cline EI, Bicciato S, DiBello C, Lingen MW. Prediction of in vivo synergistic activity of antiangiogenic compounds by gene expression profiling. Cancer Res. 2002;62:7143-7148.  [PubMed]  [DOI]  [Cited in This Article: ]
20.  Giguère CM, Bauman NM, Smith RJ. New treatment options for lymphangioma in infants and children. Ann Otol Rhinol Laryngol. 2002;111:1066-1075.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 107]  [Cited by in F6Publishing: 89]  [Article Influence: 4.0]  [Reference Citation Analysis (0)]
21.  Manley PW, Furet P, Bold G, Brüggen J, Mestan J, Meyer T, Schnell CR, Wood J, Haberey M, Huth A. Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002;45:5687-5693.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 82]  [Cited by in F6Publishing: 83]  [Article Influence: 3.8]  [Reference Citation Analysis (0)]
22.  Ranieri G, Gasparini G. Angiogenesis and angiogenesis inhibitors: a new potential anticancer therapeutic strategy. Curr Drug Targets Immune Endocr Metabol Disord. 2001;1:241-253.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 30]  [Cited by in F6Publishing: 32]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
23.  Lewy-Trenda I. [Neoplasms and angiogenesis]. Pol Merkur Lekarski. 2002;13:225-228.  [PubMed]  [DOI]  [Cited in This Article: ]
24.  Yoo GH, Piechocki MP, Ensley JF, Nguyen T, Oliver J, Meng H, Kewson D, Shibuya TY, Lonardo F, Tainsky MA. Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. Clin Cancer Res. 2002;8:3910-3921.  [PubMed]  [DOI]  [Cited in This Article: ]
25.  Lenzi R, Rosenblum M, Verschraegen C, Kudelka AP, Kavanagh JJ, Hicks ME, Lang EA, Nash MA, Levy LB, Garcia ME. Phase I study of intraperito-neal recombinant human interleukin 12 in patients with Mulle-rian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res. 2002;8:3686-3695.  [PubMed]  [DOI]  [Cited in This Article: ]
26.  Casassus P, Caillat-Vigneron N, Martin A, Simon J, Gallais V, Beaudry P, Eclache V, Laroche L, Lortholary P, Raphaël M. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol. 2002;119:1090-1097.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 110]  [Cited by in F6Publishing: 108]  [Article Influence: 4.9]  [Reference Citation Analysis (0)]
27.  Hata-Sugi N, Kawase-Kageyama R, Wakabayashi T. Character-ization of rat aortic fragment within collagen gel as an angiogen-esis model; capillary morphology may reflect the action mecha-nisms of angiogenesis inhibitors. Biol Pharm Bul. 2002;25:446-451.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 17]  [Cited by in F6Publishing: 17]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
28.  Matsunaga T, Weihrauch DW, Moniz MC, Tessmer J, Warltier DC, Chilian WM. Angiostatin inhibits coronary angiogenesis during impaired production of nitric oxide. Circulation. 2002;105:2185-2191.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 117]  [Cited by in F6Publishing: 114]  [Article Influence: 5.2]  [Reference Citation Analysis (0)]
29.  Chew LJ, Pan H, Yu J, Tian S, Huang WQ, Zhang JY, Pang S, Li LY. A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J. 2002;16:742-744.  [PubMed]  [DOI]  [Cited in This Article: ]
30.  Kalmes A, Daum G, Clowes AW. EGFR transactivation in the regulation of SMC function. Ann N Y Acad Sci. 2001;947:42-54; discussion 54-55.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 64]  [Cited by in F6Publishing: 67]  [Article Influence: 2.9]  [Reference Citation Analysis (0)]
31.  Yu J, Tian S, Metheny-Barlow L, Chew LJ, Hayes AJ, Pan H, Yu GL, Li LY. Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor. Circ Res. 2001;89:1161-1167.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 81]  [Cited by in F6Publishing: 85]  [Article Influence: 3.7]  [Reference Citation Analysis (0)]
32.  Wong ST, Baker LP, Trinh K, Hetman M, Suzuki LA, Storm DR, Bornfeldt KE. Adenylyl cyclase 3 mediates prostaglandin E(2)-induced growth inhibition in arterial smooth muscle cells. J Biol Chem. 2001;276:34206-34212.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 28]  [Cited by in F6Publishing: 31]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
33.  Stepan H, Leitner E, Bader M, Walther T. Organ-specific mRNA distribution of C-type natriuretic peptide in neonatal and adult mice. Regul Pept. 2000;95:81-85.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 29]  [Cited by in F6Publishing: 30]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
34.  Damon DH. Adrenoceptor-mediated modulation of endothelial-dependent vascular smooth muscle growth. J Auton Pharmacol. 2000;20:47-54.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5]  [Cited by in F6Publishing: 5]  [Article Influence: 0.2]  [Reference Citation Analysis (0)]
35.  Veyssier-Belot C, Cacoub P. Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension. Cardiovasc Res. 1999;44:274-282.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 64]  [Cited by in F6Publishing: 65]  [Article Influence: 2.6]  [Reference Citation Analysis (0)]
36.  Hishikawa K, Oemar BS, Tanner FC, Nakaki T, Fujii T, Lüscher TF. Overexpression of connective tissue growth factor gene induces apoptosis in human aortic smooth muscle cells. Circulation. 1999;100:2108-2112.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 76]  [Cited by in F6Publishing: 80]  [Article Influence: 3.2]  [Reference Citation Analysis (0)]
37.  Shukunami C, Iyama K, Inoue H, Hiraki Y. Spatiotemporal pattern of the mouse chondromodulin-I gene expression and its regulatory role in vascular invasion into cartilage during endochondral bone formation. Int J Dev Biol. 1999;43:39-49.  [PubMed]  [DOI]  [Cited in This Article: ]
38.  Nakano N, Higashiyama S, Takashima S, Tsuruoka N, Klagsbrun M, Taniguchi N. Purification and characterization of a novel vascular endothelial cell growth inhibitor secreted by macrophage-like U-937 cells. J Biochem. 1999;125:368-374.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2]  [Cited by in F6Publishing: 2]  [Article Influence: 0.1]  [Reference Citation Analysis (0)]
39.  Masood R, McGarvey ME, Zheng T, Cai J, Arora N, Smith DL, Sloane N, Gill PS. Antineoplastic urinary protein inhibits Kaposi's sarcoma and angiogenesis in vitro and in vivo. Blood. 1999;93:1038-1044.  [PubMed]  [DOI]  [Cited in This Article: ]
40.  Zhai Y, Ni J, Jiang GW, Lu J, Xing L, Lincoln C, Carter KC, Janat F, Kozak D, Xu S. VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J. 1999;13:181-189.  [PubMed]  [DOI]  [Cited in This Article: ]
41.  van Rees BP, Caspers E, zur Hausen A, van den Brule A, Drillenburg P, Weterman MA, Offerhaus GJ. Different pattern of allelic loss in Epstein-Barr virus-positive gastric cancer with emphasis on the p53 tumor suppressor pathway. Am J Pathol. 2002;161:1207-1213.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 36]  [Cited by in F6Publishing: 38]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
42.  Hiyama T, Tanaka S, Kitadai Y, Ito M, Sumii M, Yoshihara M, Shimamoto F, Haruma K, Chayama K. p53 Codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori-associated chronic gastritis. Int J Cancer. 2002;100:304-308.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 54]  [Cited by in F6Publishing: 56]  [Article Influence: 2.5]  [Reference Citation Analysis (0)]
43.  Murakami K, Fujioka T, Kodama M, Honda S, Okimoto T, Oda T, Nishizono A, Sato R, Kubota T, Kagawa J. Analysis of p53 mutations and Helicobacter pylori infection in human and animal models. J Gastroenterol. 2002;37 Suppl 13:1-5.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 14]  [Cited by in F6Publishing: 15]  [Article Influence: 0.7]  [Reference Citation Analysis (0)]
44.  Chang MS, Kim HS, Kim CW, Kim YI, Lan Lee B, Kim WH. Epstein-Barr virus, p53 protein, and microsatellite instability in the adenoma-carcinoma sequence of the stomach. Hum Pathol. 2002;33:415-420.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 14]  [Article Influence: 0.6]  [Reference Citation Analysis (0)]
45.  Moritani S, Sugihara H, Kushima R, Hattori T. Different roles of p53 between Epstein-Barr virus-positive and -negative gastric carcinomas of matched histology. Virchows Arch. 2002;440:367-375.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11]  [Cited by in F6Publishing: 12]  [Article Influence: 0.5]  [Reference Citation Analysis (0)]
46.  Shigeishi H, Yokozaki H, Oue N, Kuniyasu H, Kondo T, Ishikawa T, Yasui W. Increased expression of CHK2 in human gastric carcinomas harboring p53 mutations. Int J Cancer. 2002;99:58-62.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 21]  [Cited by in F6Publishing: 22]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
47.  Kubicka S, Claas C, Staab S, Kühnel F, Zender L, Trautwein C, Wagner S, Rudolph KL, Manns M. p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis. Dig Dis Sci. 2002;47:114-121.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 41]  [Cited by in F6Publishing: 44]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
48.  Fox JG, Sheppard BJ, Dangler CA, Whary MT, Ihrig M, Wang TC. Germ-line p53-targeted disruption inhibits helicobacter-in-duced premalignant lesions and invasive gastric carcinoma through down-regulation of Th1 proinflammatory responses. Cancer Res. 2002;62:696-702.  [PubMed]  [DOI]  [Cited in This Article: ]
49.  Iwamatsu H, Nishikura K, Watanabe H, Ajioka Y, Hashidate H, Kashimura H, Asakura H. Heterogeneity of p53 mutational status in the superficial spreading type of early gastric carcinoma. Gastric Cancer. 2001;4:20-26.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 15]  [Article Influence: 0.7]  [Reference Citation Analysis (0)]
50.  Jenkins GJ, Morgan C, Baxter JN, Parry EM, Parry JM. The detection of mutations induced in vitro in the human p53 gene by hydrogen peroxide with the restriction site mutation (RSM) assay. Mutat Res. 2001;498:135-144.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 9]  [Cited by in F6Publishing: 10]  [Article Influence: 0.4]  [Reference Citation Analysis (0)]
51.  Li HL, Chen DD, Li XH, Zhang HW, Lu YQ, Ye CL, Ren XD. Changes of NF-kB, p53, Bcl-2 and caspase in apoptosis induced by JTE-522 in human gastric adenocarcinoma cell line AGS cells: role of reactive oxygen species. World J Gastroenterol. 2002;8:431-435.  [PubMed]  [DOI]  [Cited in This Article: ]
52.  Satomi D, Takiguchi N, Koda K, Oda K, Suzuki H, Yasutomi J, Ishikura H, Miyazaki M. Apoptosis and apoptosis-associated gene products related to the response to neoadjuvant chemotherapy for gastric cancer. Int J Oncol. 2002;20:1167-1171.  [PubMed]  [DOI]  [Cited in This Article: ]
53.  Wu YL, Sun B, Zhang XJ, Wang SN, He HY, Qiao MM, Zhong J, Xu JY. Growth inhibition and apoptosis induction of Sulindac on Human gastric cancer cells. World J Gastroenterol. 2001;7:796-800.  [PubMed]  [DOI]  [Cited in This Article: ]
54.  Wang J, Chi DS, Kalin GB, Sosinski C, Miller LE, Burja I, Thomas E. Helicobacter pylori infection and oncogene expressions in gastric carcinoma and its precursor lesions. Dig Dis Sci. 2002;47:107-113.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 33]  [Cited by in F6Publishing: 45]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
55.  Zhang TC, Cao EH, Qin JF. Opposite biological effects of arsenic trioxide and arsacetin involve a different regulation of signaling in human gastric cancer MGC-803 cells. Pharmacology. 2002;64:160-168.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5]  [Cited by in F6Publishing: 7]  [Article Influence: 0.3]  [Reference Citation Analysis (0)]
56.  Monden N, Abe S, Hishikawa Y, Yoshimura H, Kinugasa S, Dhar DK, Tachibana M, Nagasue N. The role of P-glycoprotein in human gastric cancer xenografts in response to chemotherapy. Int J Surg Investig. 1999;1:3-10.  [PubMed]  [DOI]  [Cited in This Article: ]
57.  Wacheck V, Heere-Ress E, Halaschek-Wiener J, Lucas T, Meyer H, Eichler HG, Jansen B. Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model. J Mol Med (Berl). 2001;79:587-593.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 46]  [Cited by in F6Publishing: 48]  [Article Influence: 2.1]  [Reference Citation Analysis (0)]
58.  Enomoto A, Esumi M, Yamashita K, Takagi K, Takano S, Iwai S. Abnormal nucleotide repeat sequence in the TGF-betaRII gene in hepatocellular carcinoma and in uninvolved liver tissue. J Pathol. 2001;195:349-354.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 9]  [Cited by in F6Publishing: 9]  [Article Influence: 0.4]  [Reference Citation Analysis (0)]
59.  Shyu RY, Lin DY, Reichert U, Jiang SY. Synthetic retinoid CD437 induces cell-dependent cycle arrest by differential regulation of cell cycle associated proteins. Anticancer Res. 2002;22:2757-2764.  [PubMed]  [DOI]  [Cited in This Article: ]
60.  Li Y, Lu YY. Isolation of diallyl trisulfide inducible differentially expressed genes in human gastric cancer cells by modified cDNA representational difference analysis. DNA Cell Biol. 2002;21:771-780.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 17]  [Cited by in F6Publishing: 18]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
61.  Potthoff A, Ledig S, Martin J, Jandl O, Cornberg M, Obst B, Beil W, Manns MP, Wagner S. Significance of the caspase family in Helicobacter pylori induced gastric epithelial apoptosis. Helicobacter. 2002;7:367-377.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 21]  [Cited by in F6Publishing: 22]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
62.  Nitti D, Belluco C, Mammano E, Marchet A, Ambrosi A, Mencarelli R, Segato P, Lise M. Low level of p27(Kip1) protein expression in gastric adenocarcinoma is associated with disease progression and poor outcome. J Surg Oncol. 2002;81:167-175; discussion 175-176.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 34]  [Cited by in F6Publishing: 38]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
63.  Chen Y, Wu Q, Song SY, Su WJ. Activation of JNK by TPA promotes apoptosis via PKC pathway in gastric cancer cells. World J Gastroenterol. 2002;8:1014-1018.  [PubMed]  [DOI]  [Cited in This Article: ]
64.  Liu JR, Chen BQ, Yang YM, Wang XL, Xue YB, Zheng YM, Liu RH. Effect of apoptosis on gastric adenocarcinoma cell line SGC-7901 induced by cis-9, trans-11-conjugated linoleic acid. World J Gastroenterol. 2002;8:999-1004.  [PubMed]  [DOI]  [Cited in This Article: ]